NGS has fundamentally changed genomics research and gained the attention of many biopharmaceutical companies and research institutions across a variety of applications, such as clinical diagnostics, drug discovery and development, forensics, and consumer genomics. Next-generation sequencing provides the backbone for single-cell library preparation in order to further this technology for the development of personalized medicine. It is estimated that the cost of sequencing under the Human Genome Project was $3 billion. Ten years ago, the cost of sequencing plummeted to $200,000, compared with the current cost of $600 (BGI, China).
Global Single-Cell Multi-Omics Market (2020-2025): Focus on Product Type, Omics Type, Sample Type, Technique, Application, End User, Region, and Competitive Landscape – Analysis and Forecast, 2020-2025
Progress in the sequencing fields has paved the way for the development of massively parallel, high-throughput sequencing technologies, known as single-cell RNA sequencing and whole-genome sequencing. Compared to Sanger sequencing, whole-genome and exome sequencing technologies allow sequencing of billions of fragments in one-run while decreasing the cost per run and time. To date, progress in whole-genome and exome sequencing technologies has reduced the cost of sequencing from $10 million to approximately $1,000, and further evolution of this technology is aimed at decreasing the cost of sequencing to $100.
Further, Innovative Medicines Initiative (IMI), a strategic research agenda by the European Union with a budget of approximately $3.6 billion, is encouraging collaborations between universities, pharmaceutical and diagnostic companies, SMEs, patient organizations, regulatory bodies, and payers by financing major research projects for the development of biomarkers, companion diagnostics, and sequencing-based genetic tests.
the global single-cell multi-omics market is projected to reach $3,188.9 million by 2025 from $1,221.5 million in 2020, at a CAGR of 21.16% during the forecast period, 2020-2025.
Companies Mentioned in the Report:
• 1CellBio, Inc.
• Fluidigm Corporation
• 10x Genomics, Inc.
• NanoString Technologies, Inc.
• Bio-Techne Corporation
• Bio-Rad Laboratories, Inc.
• Mission Bio
• Dolomite Bio
• Fluxion Biosciences
• Berkeley Lights, Inc.
• RareCyte, Inc.
• Becton, Dickinson and Company
• Takara Bio, Inc.
• Thermo Fisher Scientific Inc.
• Namocell, Inc.
Key Questions Answered in this Report:
• What are the major market drivers, challenges, and opportunities in the global single-cell multi-omics market?
• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?
• What is the current market demand along with future expected demand for the global single-cell multi-omics market?
• What are the key development strategies that are implemented by the major players in order to sustain the competitive market?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2025 based on the following segments:
o product type
o omics type
o sample type
o end user
o region, namely North America, Europe, Asia-Pacific, Rest-of-the-World (RoW)
• Which are the leading players with significant offerings to the global single-cell multi-omics market? What is the expected market dominance for each of these leading players?
• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global single-cell multi-omics market?